PDE4B accounts for most of the anti-inflammatory effects [19], and PDE4D is related to emesis [20]; therefore, developing PDE4B-specific inhibitors could be a useful strategy to treat COPD. This evidence concerns the gene PDE4B and chronic obstructive pulmonary disease.